Design and in vivo evaluation of solid lipid nanoparticulate systems of Olanzapine for acute phase schizophrenia treatment: Investigations on antipsychotic potential and adverse effects

Joseph, Emil; Reddi, Satish; Rinwa, Vibhu; Balwani, Garima; Saha, Ranendra N.

doi:10.1016/j.ejps.2017.03.050

Cited by 39 publications

(22 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A lot of publications about nanocontainers involve drugs with olanzapine-a second-generation or atypical antipsychotic, which selectively binds to central dopamine D2 and serotonin (5-HT(2c)) receptors. It has poor bioavailability due to hepatic first-pass metabolism and low permeability into the brain due to efflux by P-glycoproteins [133]. Due to its low oral bioavailability, researchers have created various container preparations [134].…”

Section: Drug Delivery For Schizophrenia and Bipolar Disordersmentioning

confidence: 99%

Nano Carrier Drug Delivery Systems for the Treatment of Neuropsychiatric Disorders: Advantages and Limitations

et al. 2020

View full text Add to dashboard Cite

Neuropsychiatric diseases are one of the main causes of disability, affecting millions of people. Various drugs are used for its treatment, although no effective therapy has been found yet. The blood brain barrier (BBB) significantly complicates drugs delivery to the target cells in the brain tissues. One of the problem-solving methods is the usage of nanocontainer systems. In this review we summarized the data about nanoparticles drug delivery systems and their application for the treatment of neuropsychiatric disorders. Firstly, we described and characterized types of nanocarriers: inorganic nanoparticles, polymeric and lipid nanocarriers, their advantages and disadvantages. We discussed ways to interact with nerve tissue and methods of BBB penetration. We provided a summary of nanotechnology-based pharmacotherapy of schizophrenia, bipolar disorder, depression, anxiety disorder and Alzheimer’s disease, where development of nanocontainer drugs derives the most active. We described various experimental drugs for the treatment of Alzheimer’s disease that include vector nanocontainers targeted on β-amyloid or tau-protein. Integrally, nanoparticles can substantially improve the drug delivery as its implication can increase BBB permeability, the pharmacodynamics and bioavailability of applied drugs. Thus, nanotechnology is anticipated to overcome the limitations of existing pharmacotherapy of psychiatric disorders and to effectively combine various treatment modalities in that direction.

show abstract

Section: Drug Delivery For Schizophrenia and Bipolar Disordersmentioning

confidence: 99%

Nano Carrier Drug Delivery Systems for the Treatment of Neuropsychiatric Disorders: Advantages and Limitations

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Recent studies showed several potential psychiatric drug delivery systems using poly (lactic- co -glycolic acid) (PLGA) [ 26 ], a polyelectrolyte complexation between dextran-sulfate and dextran-chitosan [ 27 ] and solid lipids such as glyceryl monostearate [ 28 ]. Unlike these systems, which may possess disadvantages such as polymer growth, polydisperse distributions, bio-changes, toxicity, side effects, and high cost, the proteinoid nanocarriers presented in this study are biodegradable, non-toxic, and non-immunogenic.…”

Section: Introductionmentioning

confidence: 99%

Proteinoid Nanocapsules as Drug Delivery System for Improving Antipsychotic Activity of Risperidone

et al. 2020

View full text Add to dashboard Cite

Risperidone (RSP) is an atypical antipsychotic drug widely used to treat schizophrenia and bipolar disorder. Nanoparticles (NPs) are being developed as in vivo targeted drug delivery systems, which cross the blood-brain barrier and improve pharmacokinetics and drug effectiveness. Here, biodegradable proteinoids were synthesized by thermal step-growth polymerization from the amino acids l-glutamic acid, l-phenylalanine and l-histidine and poly (l-lactic acid). Proteinoid NPs containing RSP were then formed by self-assembly, overcoming the insolubility of the drug in water, followed by PEGylation (poly ethylene glycol (PEG) conjugation to increase the stability of the NPs in the aqueous continuous phase. These NPs are biodegradable owing to their peptide and ester moieties. They were characterized in terms of diameter, size distribution, drug loading, and long-term storage. Behavioral studies on mice found enhanced antipsychotic activity compared to free RSP.

show abstract

“…A promising strategy to overcome these problems involves the development of suitable drug colloidal carrier system. Among the colloidal carrier systems the solid lipid nanoparticles have many advantages as compare to other colloidal carrier systems 3 .…”

Section: Introductionmentioning

confidence: 99%

“…The advantage of SLN is, it gives more flexibility in controlling to drug release and protects the encapsulated ingredients from the degradation. Also it gives selective bio distribution, in vivo and in vitro drug stability, and better bioavailability 3,4 . Olanzapine (approved by FDA in 1996) is a novel antipsychotic agent with broad efficacy, and elicits response in both the positive and negative symptoms of schizophrenia.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Formulation and Evaluation of Solid Lipid Nanoparticles of Olanzapine for the Treatment of Psychosis

Daswadkar¹,

Atole²

2020

J. Drug Delivery Ther.

View full text Add to dashboard Cite

Solid lipid nanoparticles (SLN) are typically spherical with an average diameter between 1 nm to 1000 nm in range. It is alternative carrier systems to tradition colloidal carriers, such as liposomes emulsions and polymeric micro and nanoparticles. Olanzapine (OZP) is an atypical antipsychotic agent which is used for treatment of Schizophrenia. Its oral bioavailability is around of 40%. OZP is a class II drug so it having low aqueous solubility. To overcome that problem and to increase its bioavailability, the solid lipid nanoparticles of olanzapine are prepared. Formulation batches designed by modifying type of surfactant ( Span 80, Tween 80), concentration of surfactant, Concentration of co-surfactant, type of lipid ( glyceryl monostearate, Stearic acid), Lipid concentration, speed of stirring and time of stirring using customised design of DOE. The SLN were prepared by high speed homogenization technique, and then characterized by particle size analysis, Drug entrapment efficiency and Drug diffusion study. A formulation containing GMS as a lipid stabilised with tween 80 as surfactant show good drug release, smaller particle size, as compared with other formulations with different lipid and surfactant. The present research findings indicate that OZP loaded solid lipid Nano particulate system for delivery of OZP with better efficacy with minimum adverse effects. Keywords: Olanzapine, SLN, GMS, high speed homogenization and DOE.

show abstract

Design and in vivo evaluation of solid lipid nanoparticulate systems of Olanzapine for acute phase schizophrenia treatment: Investigations on antipsychotic potential and adverse effects

Cited by 39 publications

References 50 publications

Nano Carrier Drug Delivery Systems for the Treatment of Neuropsychiatric Disorders: Advantages and Limitations

Nano Carrier Drug Delivery Systems for the Treatment of Neuropsychiatric Disorders: Advantages and Limitations

Proteinoid Nanocapsules as Drug Delivery System for Improving Antipsychotic Activity of Risperidone

Formulation and Evaluation of Solid Lipid Nanoparticles of Olanzapine for the Treatment of Psychosis

Contact Info

Product

Resources

About